Home Companies Catalysts Deep Dives
Repatha evolocumab APPROVED
Drug Profile
ModalityMonoclonal antibody
RouteSC
Therapy AreaCVRM
Launch2015-08-27
Peak Sales Est$5000M
Formulations[{"id":"repatha-sc","doses":"140mg Q2W or 420mg QM","route":"SC","device":"SureClick autoinjector or
Companies
AMGN (ORIGINATOR)100%
Mechanism: PCSK9 inhibitor (monoclonal antibody)
Expert: Fully human IgG2 monoclonal antibody targeting PCSK9. Prevents PCSK9-mediated degradation of hepatic LDLR, increasing LDL-C clearance. SC Q2W or QM dosing.
Everyday: Blocks a protein (PCSK9) that normally destroys LDL receptors on liver cells. With PCSK9 blocked, your liver can pull more bad cholesterol out of your blood — like unclogging a drain.
Targets: ["PCSK9"]
Revenue History
PeriodRevenue ($M)
2024$2,222M
2025$3,016M
Q4 2024$606M
Q4 2025$870M
Programs (2)
IndicationStageKey StudyRegional Status
LDL-C (2ary prevention)APPROVEDFOURIER[{"stage":"APPROVED","region":"US","approval_date":"2015-08-27"}]
LDL-C (1ary prevention)PHASE3VESALIUS-CV[]
Upcoming Catalysts (1)
Repatha - Primary Prevention - VESALIUS-CV Subgroups at ACC March 2026
Data from Supabase · Updated 2026-03-24